- Home
- GEN vs BBIO Comparison
GEN vs BBIO Comparison
Compare GEN & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GEN | BBIO |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8B | 15.3B |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GEN | BBIO |
|---|---|---|
| Price | $18.66 | $72.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 25 |
| Target Price | $33.63 | ★ $83.96 |
| AVG Volume (30 Days) | ★ 5.5M | 1.7M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | ★ 7.29 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $6,676,000,000.00 | $502,076,000.00 |
| Revenue This Year | $27.40 | $88.16 |
| Revenue Next Year | $5.51 | $74.13 |
| P/E Ratio | $24.78 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $18.21 | $28.33 |
| 52 Week High | $32.22 | $84.94 |
Technical Indicators
Market Signals| Indicator | GEN | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 27.19 | 57.49 |
| Support Level | N/A | $70.65 |
| Resistance Level | $27.24 | $78.20 |
| Average True Range (ATR) | 0.69 | 2.57 |
| MACD | -0.17 | 0.48 |
| Stochastic Oscillator | 12.61 | 95.50 |
Price Performance
Historical ComparisonAbout GEN Gen Digital Inc.
Gen is a cybersecurity pure-play that offers security, identity protection, and privacy solutions to individual consumers. The firm's cyber safety offerings, via brands such as Norton, Avast, and LifeLock, have long maintained their positions as some of the most recognizable consumer-focused security and identity-protection products.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.